Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DL97UQ
|
|||
| Drug Name |
A337
|
|||
| Drug Type |
Bispecific antibody
|
|||
| Indication | Aggressive cancer [ICD-11: 2A00-2F9Z; ICD-10: R45.6; ICD-9: 140-229] | Phase 1 | [1] | |
| Company |
Klus Pharma
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Cytotoxic T-lymphocyte protein 4 (CTLA-4) | Target Info | . | [1] |
| Programmed cell death 1 ligand 1 (PD-L1) | Target Info | . | [1] | |
| KEGG Pathway | Cell adhesion molecules (CAMs) | |||
| T cell receptor signaling pathway | ||||
| Autoimmune thyroid disease | ||||
| Rheumatoid arthritis | ||||
| Pathway Interaction Database | Calcineurin-regulated NFAT-dependent transcription in lymphocytes | |||
| Reactome | CTLA4 inhibitory signaling | |||
| PD-1 signaling | ||||
| WikiPathways | Vitamin D Receptor Pathway | |||
| T-Cell Receptor and Co-stimulatory Signaling | ||||
| Allograft Rejection | ||||
| Costimulation by the CD28 family | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Clinical pipeline report, company report or official report of Klus Pharma | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.